Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show some limits in terms of tolerability and route of administration. Recently, a new oral small molecule, apremilast, has been approved for the treatment of patients with moderate-to-severe plaque psoriasis. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that regulates the transduction of intracellular signals, including pro-inflammatory and anti-inflammatory pathways. Because of the favorable safety profile and the oral route of administration, apremilast may represent a promising therapeutic target for moderate-to-severe psoriasis. In this review, we report an updated overview about clinical trials testing apremilast in the treatment of psoriasis and seek to provide comprehensive information about this anti-psoriatic drug and a future perspective of the therapeutic algorithm for psoriasis.

Chiricozzi, A., Caposiena, D., Garofalo, V., Cannizzaro, M. V., Chimenti, S., Saraceno, R., A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: Apremilast, <<EXPERT REVIEW OF CLINICAL IMMUNOLOGY>>, 2016; 12 (3): 237-249. [doi:10.1586/1744666X.2016.1134319] [http://hdl.handle.net/10807/200347]

A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: Apremilast

Chiricozzi, Andrea;
2016

Abstract

Psoriasis is a common, chronic, inflammatory skin disease. Being a life-long condition, a prolonged and safe control of the disease is needed. Current anti-psoriatic treatments show some limits in terms of tolerability and route of administration. Recently, a new oral small molecule, apremilast, has been approved for the treatment of patients with moderate-to-severe plaque psoriasis. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that regulates the transduction of intracellular signals, including pro-inflammatory and anti-inflammatory pathways. Because of the favorable safety profile and the oral route of administration, apremilast may represent a promising therapeutic target for moderate-to-severe psoriasis. In this review, we report an updated overview about clinical trials testing apremilast in the treatment of psoriasis and seek to provide comprehensive information about this anti-psoriatic drug and a future perspective of the therapeutic algorithm for psoriasis.
2016
Inglese
Chiricozzi, A., Caposiena, D., Garofalo, V., Cannizzaro, M. V., Chimenti, S., Saraceno, R., A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: Apremilast, <<EXPERT REVIEW OF CLINICAL IMMUNOLOGY>>, 2016; 12 (3): 237-249. [doi:10.1586/1744666X.2016.1134319] [http://hdl.handle.net/10807/200347]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/200347
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 37
social impact